Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | CASP1 | P29466 | 1/20 | 0.40 |
| ▸ | CASP7 | P55210 | 1/20 | 0.40 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.40 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.40 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.40 |
| ▸ | MPI | P34949 | 1/20 | 0.40 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6776942 | 0.85 | ALDH1A1 (0.46) | GAALMNASMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL11473911 | 0.82 | GAA (0.43) | GAAMAPK1L3MBTL1LMNASMN1; SMN2 | |
| SCHEMBL10745237 | 0.82 | GAA (0.44) | GAAMAPK1L3MBTL1LMNASMN1; SMN2 | |
| SCHEMBL8332616 | 0.81 | GAA (0.50) | GAAMAPK1L3MBTL1LMNASMN1; SMN2 | |
| SCHEMBL6141592 | 0.81 | NAMPT (0.42) | GAAL3MBTL1LMNANPSR1ALDH1A1 | |
| SCHEMBL1516027 | 0.81 | MMP8 (0.53) | GAALMNASMN1; SMN2TSHRMAPT | |
| SCHEMBL10827291 | 0.80 | SMN1; SMN2 (0.51) | GAAMAPK1L3MBTL1LMNASMN1; SMN2 | |
| SCHEMBL1605240 | 0.80 | CYP19A1 (0.56) | GAAMAPK1L3MBTL1LMNASMN1; SMN2 | |
| SCHEMBL14445303 | 0.80 | GAA (0.47) | GAAMAPK1L3MBTL1LMNASMN1; SMN2 | |
| SCHEMBL234521 | 0.79 | GAA (0.48) | GAAMAPK1L3MBTL1LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8334381-B2 | Process for the preparation of intermediates useful in the synthesis of imatinib | F.I.S. FABBRICA ITALIANA SINTETICI S.P.A. (IT) | 2012-12-18 | — | — | US | claimed |
| US-20100234598-A1 | PROCESS FOR THE PREPARATION OF IMATINIB AND INTERMEDIATES THEREOF | FALCHI ALESSANDRO | 2010-09-16 | — | — | US | claimed |
| EP-2074095-A2 | PROCESS FOR THE PREPARATION OF IMATINIB AND INTERMEDIATES THEREOF | F.I.S. Fabbrica Italiana Sintetici S.p.A. (IT) | 2009-07-01 | — | — | EP | claimed |
| WO-2008059551-A2 | PROCESS FOR THE PREPARATION OF IMATINIB AND INTERMEDIATES THEREOF | F.I.S. FABBRICA ITALIANA SINTETICI S.P.A. (IT) | 2008-05-22 | — | — | WO | claimed |
| EP-2074095-B1 | PROCESS FOR THE PREPARATION OF IMATINIB AND INTERMEDIATES THEREOF | ITALIANA SINT SPA (IT) | 2014-07-02 | — | — | EP | disclosed |
| US-8334381-B2 | Process for the preparation of intermediates useful in the synthesis of imatinib | F.I.S. FABBRICA ITALIANA SINTETICI S.P.A. (IT) | 2012-12-18 | — | — | US | disclosed |
| US-8168787-B2 | Process for the preparation of imatinib and intermediates thereof | F.I.S. FABBRICA ITALIANA SINTETICI S.P.A. (IT) | 2012-05-01 | — | — | US | disclosed |
| US-20100234598-A1 | PROCESS FOR THE PREPARATION OF IMATINIB AND INTERMEDIATES THEREOF | FALCHI ALESSANDRO | 2010-09-16 | — | — | US | disclosed |
| US-20100076189-A1 | PROCESS FOR THE PREPARATION OF IMATINIB AND INTERMEDIATES THEREOF | F.I.S. FABBRICA ITALIANA SINTETICI S.P.A. (IT) | 2010-03-25 | — | — | US | disclosed |
| EP-2074095-A2 | PROCESS FOR THE PREPARATION OF IMATINIB AND INTERMEDIATES THEREOF | F.I.S. Fabbrica Italiana Sintetici S.p.A. (IT) | 2009-07-01 | — | — | EP | disclosed |
| WO-2008059551-A2 | PROCESS FOR THE PREPARATION OF IMATINIB AND INTERMEDIATES THEREOF | F.I.S. FABBRICA ITALIANA SINTETICI S.P.A. (IT) | 2008-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100076189-A1 | PROCESS FOR THE PREPARATION OF IMATINIB AND INTERMEDIATES THEREOF | ABL1, PDGFRA, ABL2 | GAA 1283/4885MAPK1 492/4885L3MBTL1 2847/4885 |
| US-20100234598-A1 | PROCESS FOR THE PREPARATION OF IMATINIB AND INTERMEDIATES THEREOF | ABL1, PDGFRA, ABL2 | GAA 1283/4885MAPK1 492/4885L3MBTL1 2847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.